No Data
No Data
Express News | Vanda Pharmaceuticals Shares up 2% Premarket After Its Motion Sickness Treatment Succeeds in a Late-Stage Confirmatory Study
Express News | Vanda Pharmaceuticals: 2Nd Phase III Study Showed Tradipitant Is Effective in Prevention of Vomiting Associated With Motion Sickness
Express News | Vanda Pharmaceuticals Inc - New Drug Application Expected to Be Submitted in Q4 2024
Express News | Vanda Pharmaceuticals Reports Positive Results From a Second Phase III Study of Tradipitant in Motion Sickness
Vanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue Estimates
Earnings Call Summary | Vanda Pharmaceuticals(VNDA.US) Q1 2024 Earnings Conference
The following is a summary of the Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript:Financial Performance:Vanda Pharmaceuticals posted total revenues of $47.5 million for Q1 2024, re
No Data